Behavioral Economic Incentives to Improve Medication Adherence and Outcomes Among Patients in United States With HIV: A Feasibility Study
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Human Immunodeficiency Virus
- Sponsor
- University of Pennsylvania
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Number of patients with viral suppression
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
With support from the NIH, this pilot study will assess the feasibility of using wireless devices and financial incentives to motivate medication adherence among HIV-positive adults in the U.S., focusing on those with non-suppressed viral loads.
While daily lotteries using wireless devices may have great potential for improving adherence to ART regimens, substantial questions exist as to whether it is: 1) possible to achieve high rates of uptake for a pilot offering wireless devices to high-risk populations; 2) achieve high rates of sustained engagement.
Detailed Description
The goal of this study is to explore the feasibility of using wireless devices and financial incentives to motivate medication adherence among high-risk HIV positive patients. By partnering with the Drexel Partnership Comprehensive Care Clinic at Drexel University, the investigators will be able to identify such patients using clinic patient data, use clinic and physician communication channels to enroll them, and maintain high levels of ongoing participation through the use of incentives. The aim is to improve antiretroviral medication adherence among high-risk HIV positive patients by providing patients with a AdhereTech device (electronic pill bottle), daily adherence notifications tracked by the Way to Health platform, as well as daily lotteries and financial incentives. Upon completion, this study will answer questions important to the feasibility of conducting well-powered randomized controlled trials to improve adherence among HIV patients within the U.S. who have sub-optimal adherence.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of HIV, established in 2017 or earlier
- •Patients at least 18 years of age or older
- •Currently prescribed first or second line ART medications
- •Non-suppressed viral loads, with two consecutive non-suppressed viral loads (VL\>400 copies/ml) for the past two lab readings.
Exclusion Criteria
- •Prescribed Maraviroc or Fuzeon
- •More than 5 additional medications
- •Diagnosed with insulin dependent diabetes
- •Unable to provide consent
- •Non-English speaker
- •Cognitive impairment, per PI discretion
- •Does not have stable residence
Outcomes
Primary Outcomes
Number of patients with viral suppression
Time Frame: approximately 3 months after enrollment
viral load less than 400
Secondary Outcomes
- number of clinic visits by arm(approximately 3 months after enrollment)
- viral suppression by arm(approximately 3 months after enrollment)
- medication adherence by arm(approximately 3 months after enrollment)
- Recruitment rates by arm(approximately 3 months after enrollment)
- Percent of patients that use electronic pill bottle(approximately 3 months after enrollment)
- Attrition rates by arm(approximately 3 months after enrollment)
- Completion rates of lab visit by arm(approximately 3 months after enrollment)